Director Jean Francois Formela sold 171,405 shares (50.3% of holdings) for $2,458,582.35 via pre-arranged 10b5-1 plan; stock -75.4% from 52-week high.
Jean Francois Formela, a director at Korro Bio, executed 8 separate sales totaling 171,405 shares for $2,458,582.35 over three trading days (June 22–24, 2026) at prices ranging from $13.95 to $14.98, reducing his holdings by 50.3%. This transaction was conducted pursuant to a pre-arranged 10b5-1 trading plan adopted on 2026-04-08, meaning the sales were scheduled and not discretionary decisions. The company remains unprofitable with net income of $-19,625,000.00, though it reported annual revenue growth of +181.5%. The current stock price of $13.77 is -75.4% from the 52-week high of $55.89, indicating significant deterioration in value since the plan's adoption in April. While 10b5-1 sales do not reflect timing decisions, the substantial reduction of director holdings by one-half during a period of steep stock decline and ongoing losses is a material corporate action warrant monitoring for shareholder context.